[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

COVID-19 Therapy and Vaccine Drug Pipeline and Clinical Trials Report- January 2021 update

January 2021 | 2400 pages | ID: CC90D612E3DAEN
VPAResearch

US$ 4,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The comprehensive 2,400 page research study on COVID-19 therapeutic and vaccine pipeline candidates, completed, ongoing and planned clinical trials across phases, countries, companies and institutes/hospitals.

The global COVID-19 market size outlook remains robust driven by huge potential for administration to 2 billion populations, vast diagnostics market revenue outlook, marketing agreements with governments, approval and launch of diverse drugs and ongoing investments in R&D pipeline of COVID-19 will strengthen the market demand.

COVID Pipeline Snapshot, January 2021

COVID-19 pipeline comprises of 639 drug candidates under development as of December 2020. The pipeline is characterized by presence of both large scale companies and small players. Large companies including Novartis, Pfizer, Zydus, Roche, Sanofi and GlaxoSmithKline continue to invest in treatment options vaccination candidates.

Among pre-clinical and research phase candidates, several companies are looking for partnering with other companies or universities to advance their research studies.

‘Immunostimulants’ is among the most researched ‘mechanism of action’ in the pipeline.

Among drug and vaccine candidates in clinical trials (Phase 1 to Phase 3), 155 of 263 candidates are new molecular entities.

Of the 639 drug candidates in development, 75 drug/vaccine candidates are identified in Phase 3 while 131 candidates are in Phase 2. 55 candidates are in Phase 1 and 235 candidates are in preclinical study phase. Further, the number of drug and vaccine candidates in research study phase stood at 134.

COVID Clinical Trials Snapshot, 2021

During the observation period, 1726 COVID-19 trials have been initated and an additional 534 clinical trials are planned to commence. Of the total 2260 trials studied in the research, 957 trials are in Phase 2, 748 trials are in Phase 3, 321 trials in Phase 0 and Phase 1, and 228 trials in Phase 4. In terms of enrollment, 70% of subjects are recruited/or planned for Phase 3.

Around 78% of trials are recruiting or planning to recruit subjects for their pipeline product development. Over 26% of trials are directly sponsored by pharmaceutical companies with the remaining 74% being sponsored indirectly by companies or sponsored by institutions.

Among countries, the US stood the largest market worldwide, accounting for 539 clinical trials. Among economy types, advanced and emerging economies share an almost equal volume of trials with the former accounting for 52% of trial count.

Scope of the report-
  • COVID-19 pipeline report identifies 650+ companies active in 2021
  • Pre-clinical drug candidates, research phase COVID-19 compounds, New Molecular entities, Phase 0, Phase 1, Phase 2, Phase 3, Pre-registration, IND and other phase COVID-19 pipeline products are included
  • Business profiles and snapshots of all major companies are presented in the report
  • Recent market developments in the COVID-19 vaccines and treatment products
  • 1500+ Clinical trials details including snapshot, companies, institutes, phase, start date, completion date, recruitment, enrolment and other details
  • Drug candidate, Vaccine candidate details including current status, companies involved, new molecular entity, phase, mechanism of action, recent developments, route of administration and other details analyzed for each candidate
1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 EXECUTIVE SUMMARY

2.1 Pipeline Snapshot
2.2 Pipeline Drugs by Phase
2.3 Pipeline Drugs by New Molecular Entity
2.4 Pipeline Drugs by Mechanism of Action
2.5 Major Drugs in COVID-19 Pipeline
  2.5.1 Authorized Stage
  2.5.2 Registered Stage
  2.5.3 Phase 3 Stage
  2.5.4 Phase 2/3 Stage
  2.5.5 Phase 2 Stage
  2.5.6 Phase 1/2 Stage
  2.5.7 Phase 1 Stage
2.6 COVID-19 Clinical Trials Overview, 2021
2.7 Premium Insights into Clinical Trials
  2.7.1 United States is the largest country in COVID-19 Clinical Trials
  2.7.2 COVID-19 Clinical Trials by Region
  2.7.3 One-Fifth of trials are directly sponsored by Companies
  2.7.4 Companies participating in Trials
  2.7.5 Trials in Emerging and Developing Economies

3 REGION-WISE COVID-19 CLINICAL TRIALS

3.1 North America COVID-19 Clinical Trials by Country
3.2 Europe COVID-19 Clinical Trials by Country
3.3 Asia Pacific COVID-19 Clinical Trials by Country
3.4 Middle East and Africa COVID-19 Clinical Trials by Country
3.5 South and Central America COVID-19 Clinical Trials by Country

4 CLINICAL TRIALS TRENDS TO 2025

4.1 Phase wise COVID-19 Clinical Trials
4.2 COVID-19 Trials by Recruitment Status
4.3 Trial Type wise COVID-19 Clinical Trials

5 COVID-19 AVERAGE ENROLLMENT TRENDS

5.1 Enrollment in COVID-19 Trials by Region
5.2 Enrollment in Top 10 Countries- COVID-19 Trials
5.3 Enrollment in COVID-19 Trials by Phase
5.4 Enrollment in COVID-19 Trials by Status
5.5 Enrollment in COVID-19 Trials by Type of Trial

6 COMPANY LEVEL ANALYSIS

6.1 COVID-19 Trials by Sponsor Type
6.2 COVID-19 Average Enrollment by Sponsor Type
  6.2.1 Subjects Recruited by Leading Sponsors
  6.2.2 Leading Institutes participating in Clinical Trials

7 RECENT CLINICAL TRIALS- SNAPSHOTS

7.1 Phase 0 Trials
7.2 Phase 1 Trials
7.3 Phase 2 Trials
7.4 Phase 3 Trials
7.5 Phase 4 Trials

8 APPENDIX

8.1 ABOUT VPA RESEARCH
8.2 SOURCES AND RESEARCH METHODOLOGY

LIST OF FIGURES

Figure 1: Epidemic curve of confirmed COVID-19 Cases, December 2019- December 2020
Figure 2: COVID-19 Pipeline by Phase, December 2020
Figure 3: COVID-19 Pipeline by MOA, December- 2020
Figure 4: COVID-19- Clinical Trials by Country, 2020
Figure 5: COVID-19- Clinical Trials by Region, 2020
Figure 6: COVID-19- Clinical Trials by Type of Economy
Figure 7: COVID-19- Clinical Trials by Phase of Development
Figure 8: COVID-19- Clinical Trials by Status
Figure 9: COVID-19- Clinical Trials by Type
Figure 10: Enrollment in COVID-19 Trials by Region
Figure 11: COVID-19- Trials by Sponsor Type
Figure 12: COVID-19- Enrollment by Sponsor Type

LIST OF TABLES

Table 1: COVID-19 Pipeline by Phase, December 2020
Table 2: COVID-19 Pipeline by New Molecular Entity, December- 2020
Table 3: COVID-19 Pipeline by Mechanism of Action, December 2020
Table 4: COVID-19 Pipeline Drugs in Authorized Stage
Table 5: COVID-19 Pipeline Drugs in Registered Stage
Table 6: COVID-19 Pipeline Drugs in Phase 3
Table 7: COVID-19 Pipeline Drugs in Phase 2/3
Table 8: COVID-19 Pipeline Drugs in Phase 2
Table 9: COVID-19 Pipeline Drugs in Phase 1/2
Table 10: COVID-19 Pipeline Drugs in Phase 1
Table 11: COVID-19- Unique Clinical Trials by Sponsor Type
Table 12: North America- COVID-19 Clinical Trials by Country
Table 13: Europe - COVID-19 Clinical Trials by Country
Table 14: Europe - COVID-19 Clinical Trials by Country (Continued)
Table 15: Asia Pacific - COVID-19 Clinical Trials by Country
Table 16: Middle East and Africa - COVID-19 Clinical Trials by Country
Table 17: Middle East and Africa - COVID-19 Clinical Trials by Country (continued)
Table 18: South and Central America - COVID-19 Clinical Trials by Country
Table 19: Enrollment in COVID-19 Trials by Region
Table 20: COVID-19- Top 10 Countries with Enrollment
Table 21: COVID-19- Enrollment by Phase
Table 22: COVID-19- Enrollment by Phase
Table 23: COVID-19- Enrollment by Trial Type
Table 24: COVID-19- Subjects Recruited by Leading Sponsors
Table 25: COVID-19 Phase 0 Trial Snapshots
Table 26: COVID-19 Phase 0 Trial Snapshots
Table 27: COVID-19 Phase 0 Trial Snapshots
Table 28: COVID-19 Phase 0 Trial Snapshots
Table 29: COVID-19 Phase 0 Trial Snapshots
Table 30: COVID-19 Phase 0 Trial Snapshots
Table 31: COVID-19 Phase 0 Trial Snapshots
Table 32: COVID-19 Phase 0 Trial Snapshots
Table 33: COVID-19 Phase 0 Trial Snapshots
Table 34: COVID-19 Phase 0 Trial Snapshots
Table 35: COVID-19 Phase 0 Trial Snapshots
Table 36: COVID-19 Phase 0 Trial Snapshots
Table 37: COVID-19 Phase 0 Trial Snapshots
Table 38: COVID-19 Phase 0 Trial Snapshots
Table 39: COVID-19 Phase 0 Trial Snapshots
Table 40: COVID-19 Phase 0 Trial Snapshots
Table 41: COVID-19 Phase 0 Trial Snapshots
Table 42: COVID-19 Phase 0 Trial Snapshots
Table 43: COVID-19 Phase 0 Trial Snapshots
Table 44: COVID-19 Phase 0 Trial Snapshots
Table 45: COVID-19 Phase 0 Trial Snapshots
Table 46: COVID-19 Phase 0 Trial Snapshots
Table 47: COVID-19 Phase 0 Trial Snapshots
Table 48: COVID-19 Phase 0 Trial Snapshots
....
Table 118: COVID-19 Phase 1 Trial Snapshots
Table 119: COVID-19 Phase 1 Trial Snapshots
Table 120: COVID-19 Phase 1 Trial Snapshots
Table 121: COVID-19 Phase 1 Trial Snapshots
Table 122: COVID-19 Phase 1 Trial Snapshots
...
Table 2272: COVID-19 Phase 4 Trial Snapshots 2414
Table 2273: COVID-19 Phase 4 Trial Snapshots 2415
Table 2274: COVID-19 Phase 4 Trial Snapshots 2416
Table 2275: COVID-19 Phase 4 Trial Snapshots 2417
Table 2276: COVID-19 Phase 4 Trial Snapshots 2418
Table 2277: COVID-19 Phase 4 Trial Snapshots 2419
Table 2278: COVID-19 Phase 4 Trial Snapshots 2420
Table 2279: COVID-19 Phase 4 Trial Snapshots 2421
Table 2280: COVID-19 Phase 4 Trial Snapshots 2422
Table 2281: COVID-19 Phase 4 Trial Snapshots 2423
Table 2282: COVID-19 Phase 4 Trial Snapshots 2424
Table 2283: COVID-19 Phase 4 Trial Snapshots 2425
Table 2284: COVID-19 Phase 4 Trial Snapshots 2426

COMPANIES MENTIONED (IF APPLICABLE)

Novartis Pharmaceuticals, Azidus Brasil, Eli Lilly and Company, Hamad Medical Corporation, Gilead Sciences, Genentech, Inc., ProgenaBiome, Revimmune, Regeneron Pharmaceuticals, AstraZeneca, Romark Laboratories L.C., Ridgeback Biotherapeutics, LP, Cadila Pharnmaceuticals, NeuroRx, Inc., Hoffmann-La Roche, Hope Biosciences, China National Biotec Group Company Limited, Medicine Invention Design, Inc, Azienda Ospedaliero-Universitaria di Parma, Merck Sharp & Dohme Corp., Kaleido Biosciences, Pulmotect, Inc., Beijing TIL Therapeutics, CanSino Biologics Inc., Vakzine Projekt Management GmbH, Intermountain Health Care, Inc., ModernaTX, Inc., Incyte Corporation, Sorrento Therapeutics, Inc., IRCCS San Raffaele, Sina Darou Laboratories Company, Sanofi, Max Healthcare Insititute Limited, CytoDyn, Inc., World Medicine ILAC SAN. ve TIC. A.S., Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., Implicit Bioscience, Karyopharm Therapeutics Inc, Octapharma, Kiniksa Pharmaceuticals, Ltd., Atabay Kimya Sanayi Ticaret A.S., R-Pharm, Instituto Grifols, S.A., Cadila Healthcare Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Brii Biosciences Limited, NeuroActiva, Inc., Bristol-Myers Squibb, SAb Biotherapeutics, Inc., Theravance Biopharma, Sound Pharmaceuticals, Incorporated, Sinovac Research and Development Co., Ltd., Glenmark Pharmaceuticals Ltd, Laboratorio Elea Phoenix S.A., CinnaGen Company, Inmunotek S.L., Alexion Pharmaceuticals, RedHill Biopharma Limited, Shire, Dr Reddys Laboratories Limited, Generon (Shanghai) Corporation Ltd., Hamilton Health Sciences Corporation, Durect Corp, CAR-T (Shanghai) Biotechnology Co., Ltd., BioCryst Pharmaceuticals, Janssen Research & Development, LLC, Oryzon Genomics S. A., Humanigen, Inc., Hunan yuanpin Cell Biotechnology Co., Ltd, Kinevant Sciences GmbH, I-Mab Biopharma Co. Ltd., AbbVie, Perseverance Research Center, LLC, Regeneris Medical, Personalized Stem Cells, Inc., UnitedHealth Group, Janssen Pharmaceutical K.K., BeiGene, International Stemcell Services Ltd, Bausch Health Americas, Inc., Barakat Pharmaceutical Group, BioAegis Therapeutics Inc., Genexine, Inc., Fujifilm Pharmaceuticals U.S.A., Inc., Staidson (Beijing) Biopharmaceuticals Co., Ltd, Azienda USL Toscana Nord Ovest, Ampio Pharmaceuticals. Inc., 4D pharma plc, AnGes, Inc., GlaxoSmithKline, Biophytis, Renibus Therapeutics, Inc., Rapa Therapeutics LLC, Celularity Incorporated, Evelo Biosciences, Inc., IBSA Institut Biochimique SA, Chiesi Farmaceutici S.p.A., AVM Biotechnology LLC, Firebrick Pharma Pty Ltd, Athersys, Inc, Pharmamel S.L., BioNTech SE, Shree Dhootapapeshwar Limited, Novavax, Kimera Labs, OncoImmune, Inc., Burnasyan Federal Medical Biophysical Center, Inmune Bio, Inc., Northside Hospital, Inc., Swedish Orphan Biovitrum, AI Therapeutics, Inc., Bosnalijek D.D, Appili Therapeutics Inc., Covis Pharma S.?.r.l., Baylx Inc., Vanda Pharmaceuticals, Vaxine Pty Ltd, Immunic AG, AO GENERIUM, TASK Applied Science, Pulmoquine Therapeutics, Inc, R-Pharm International, LLC, Corvus Pharmaceuticals, Inc., Immunitor LLC, Heron Therapeutics, BioNTech RNA Pharmaceuticals GmbH, Shin Poong Pharmaceutical Co. Ltd., Janssen Pharmaceutica N.V., Belgium, Arcturus Therapeutics, Inc., NPO Petrovax, Alfasigma S.p.A., MGC Pharmaceuticals d.o.o, RSV Therapeutics LLC, PharmaMar, Restem, LLC., Qu?mica Luar SRL, Enzychem Lifesciences Corporation, Algernon Pharmaceuticals, Amarin Corporation, Synairgen Research Ltd., Aerpio Therapeutics, ImmunityBio, Inc., Cynata Therapeutics Limited, Canadian Cancer Trials Group, argenx BV, InflaRx GmbH, Klinikum St. Georg gGmbH, Veru Inc., Biohaven Pharmaceuticals, Inc., Pluristem Ltd., Apex Laboratories Pvt Ltd, Windtree Therapeutics, Sun Pharmaceutical Industries Limited, Chimerix Inc, Darmanara .Co, BioXcellerator, Hilton Pharma Pvt. Ltd., Leading BioSciences, Inc, DEY Company, Can-Fite BioPharma, Capricor Inc., Blade Therapeutics, Sentien Biotechnologies, Inc., TriHealth Inc., Bayside Health, Abivax S.A., Applied Biology, Inc., Lifefactors Zona Franca, SAS, Sharp HealthCare, Amyndas Pharmaceuticals S.A., CureVac AG, Atea Pharmaceuticals, Inc., Medicago Inc, Biocad, Vicore Pharma AB, NantKwest, Inc., Chugai Pharmaceutical Co., Ltd., Aspire Health Science, Beyond Air Ltd, Aivita Biomedical, Inc., Orpheris, Inc., Novelfarma Ila? San. ve Tic. Ltd. Sti., Angion Biomedica Corp, Hope Pharmaceuticals, Thirty Respiratory Limited, Apellis Pharmaceuticals, Inc., Laboratorios Roemmers S.A.I.C.F., Arch Biopartners Inc., Ansun Biopharma, Inc., Cardiologia Assistencial e de Pesquisa LTDA, Takeda, Benefic?ncia Portuguesa de S?o Paulo, Cellenkos, Inc., VistaGen Therapeutics, Inc., Bharat Biotech International Limited, Symvivo Corporation, Kentucky BioProcessing, Inc., Clover Biopharmaceuticals AUS Pty Ltd, Biocon Limited, S.L.A. Pharma AG, Grifols Therapeutics LLC, Biofarma, Humanetics Corporation, Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V., Sinocelltech Ltd., GeneOne Life Science, Inc., Thomas Benfield, Restorbio Inc., Medigen Vaccine Biologics Corp., CSL Behring, Regenexx, LLC, Mesoblast International S?rl, Nutrin GmbH, Partner Therapeutics, Inc., Inmunova S.A., Aevi Genomic Medicine, LLC, Biopharma Plasma LLC, aTyr Pharma, Inc., NeoImmuneTech, Apeiron Biologics, Revive Therapeutics, Ltd., CTI BioPharma, PT Bio Farma, Laurent Pharmaceuticals Inc., Orthosera Kft., Telios Pharma, Inc., Fulcrum Therapeutics, Bellerophon Pulse Technologies, Accelagen Pty Ltd, Clear Creek Bio, Inc., Erasmus MC, Zhejiang Hisun Pharmaceutical Co. Ltd., AB Science, HeNan Sincere Biotech Co., Ltd, Charit? Research Organisation GmbH, Celltex Therapeutics Corporation, DRK-Bluspendedienst Baden-W?rttemberg - Hessen gGmbH, Inotrem, St George Street Capital Ltd, Tychan Pte Ltd., WIN MEDICARE PVTLTD, MediciNova, Intas Pharmaceuticals Ltd, Trustem, Wockhardt Ltd, FibroGen, Cipla Ltd, Inovio Pharmaceuticals, Cadila Healthcare Limited Zydus Research Center, Bio-Thera Solutions, PHARCO CORPORATE, PhaseBio Pharmaceuticals Inc., FUJIFILM Toyama Chemical Co., Ltd., Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen, Chistasazan Notash Fartak Company Limited., Chromis LLC, Zist Daru Danesh Company, First Wave Bio, Inc., Middle East Gene Therapy corporation, PTC Therapeutics, Tuohua Biological Technology Co. Ltd, Sanotize Research and Development corp., Health Medicine Chemistry Company, Immunovative Therapies, Ltd., Bukwang Pharmaceutical, Shanghai Junshi Bioscience Co., Ltd., AdventHealth, Altimmune, Inc., Kocak Farma, ViralClear Pharmaceuticals, Inc.


More Publications